Guava vs Aidy for Ulcerative Colitis: Records or IBD Focus?
By the Aidy Editorial Team
First Published May 8, 2026Last Updated Aug 19, 2026
Guava's listing describes a broad medical-record hub, while Aidy provides a ready-made UC workflow for symptoms, treatment, trends, and reports. Guava claims portal imports, device connections, and multi-condition tracking. Aidy connects daily symptoms and stool with treatment, disease-activity trends, and reports using less configuration. A systematic review shows IBD apps span several functions.
Quick answer: For most people with UC, choose Aidy for a free primary record with daily logging, biologic tools, SCCAI trends, and clinician reports. Guava is the genuine exception for someone needing its claimed patient-portal imports, device connections, Android or web access, and family management.
| Decision factor | Aidy | Guava (public claims) |
|---|---|---|
| Best for | Ready-made UC care | Claims record aggregation |
| Daily IBD record | Stool, symptoms, food, treatment | Claims custom health and device data |
| Treatment tools | Detailed biologic schedules | Claims medicine tracking and imports |
| Reports and insights | SCCAI and reports | Claims summaries, exports, sharing |
| Access and cost | Free | Claims free tier plus Premium |
| Overall pick | Aidy | Health-archive exception |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
Guava Is the Stronger Medical-Record Hub
A Guava Health review IBD comparison starts with aggregation. Its listing claims connections to 50,000 US providers plus notes, labs, imaging, prescriptions, procedures, PDFs, and CCDA files. The listing says device integrations add sleep, activity, glucose, and heart rate, making Guava a capable patient portal health tracker.
Guava's FAQ claims symptoms, medicines, bowel and urine logs, food, mood, energy, cycle data, activities, habits, and custom fields. It also claims Visit Prep, exports, sharing links, and a provider dashboard. Aidy does not aggregate portals or imaging. Guava wins for consolidating care across specialties.
That breadth is valuable when UC is one part of complex care.
UC Focus Changes What the Daily Record Means
A broad tracker can capture almost anything, but users must define their UC system. NIDDK lists diarrhea, rectal bleeding, abdominal pain, mucus, tenesmus, and urgency among common UC symptoms. Based on Guava's advertised custom fields, users could represent these as custom entries, yet its public materials do not describe a dedicated UC score or preset IBD workflow.
Aidy tracks symptoms, Bristol stool, meals, adherence, food associations, and SCCAI. The SCCAI study covers bowel frequency, urgency, blood, wellbeing, and extracolonic features. It remains symptom-oriented. AGA recommends combining symptoms with biomarkers, while NIDDK describes laboratory and endoscopic assessment.
Aidy supplies that UC structure from the first entry.
Treatment Tracking Gives Aidy the Daily Advantage
Guava claims a strong general medication system. Its materials describe schedule and dose logs, reminders, pill-supply monitoring, refill alerts, and treatment-to-symptom comparisons. They also say imported portal records keep the formal medication list near other history. Those capabilities may be enough for oral medicines.
Aidy adds biologic induction and maintenance schedules, reminders, countdowns, injection-site rotation, post-dose check-ins, adherence, and interval changes beside symptoms, stool, meals, and SCCAI. NIDDK says UC treatment may include biologics, other medicines, or surgery. An adherence review found multicomponent interventions most successful, supporting evaluation beyond a medicine-field count.
That treatment continuity is the central daily-management advantage.
Platforms and Privacy Favor Guava's Broad Reach
Guava has the platform advantage. Its pricing page says the service works worldwide on web, iOS, and Android in more than 20 languages. Aidy's native app is iPhone-only, though Aidy offers SMS access in the United States. Guava is easier for Android users, mixed-device households, or anyone wanting desktop access.
Guava also publishes unusually specific security information. Its privacy and security page says data is encrypted with AES-256 at rest and TLS 1.3, or at least 1.2, in transit. It says information is never sold, used for advertising, or shared without permission, and users can delete stored data. The fuller privacy policy explains that connected portal data is stored, some third-party processors help deliver the service, and authorized staff may view data when necessary for support. Aidy data is encrypted, exportable, deletable, and never sold. Both still warrant a personal review before storing longitudinal health records.
Guava Premium Price and the Better UC Choice
Guava's current plans page makes the free boundary clear. The page says the $0 plan includes portal and device syncing, manual tracking, simple summaries and correlations, sharing, uploads, and all three platforms. It lists Guava Premium at $8 monthly or $78 annually and claims it adds automatic insights, unlimited family or caregiver managers, laboratory-result extraction, AI assistance, food-photo nutrient detection, and an emergency card. That generous free plan makes Guava a credible ulcerative colitis records app.
Aidy is free to use with no paid user subscriptions. That free access includes its complete UC workflow and continuing appointment reports. Aidy is the better Guava alternative for daily UC management because it supplies the symptom structure, SCCAI trend, biologic logistics, adherence context, and IBD-focused report without making users design those connections. Guava remains the better record aggregator. Many people could keep Guava as their master archive and Aidy as their daily disease-management record.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.